Harnessing the power of genetic medicines
Genetic medicines have the potential to transform the treatment of human disease across a wide range of therapeutic applications. Yet, the broad application of genetic medicines remains largely limited by available delivery technologies. Sigma was founded with a vision to unlock the potential of genetic medicines to revolutionize human health.
Learn more →Delivering on genetic medicines
Sigma's mission is to unlock the potential of genetic medicines by tacking the greatest unmet need in the field today – delivery. Sigma has multiple proprietary delivery platforms including targeted lipid nanoparticles (tLNPs), antibody oligonucleotide conjugates (AOCs), and protein nanoparticles (PNPs), that are being developed to enable next-generation genetic medicines across a range of therapeutic modalities and disease areas.
These platforms have the potential to overcome the limitations of today's delivery technologies and expand the application of genetic medicines.
Our Science →